Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
|
|
Sienna Biopharmaceuticals, Inc. (SNNA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2020 |
SC 13G/A
| FMR LLC reports a 13.9% stake in SIENNA BIOPHARMACEUTICALS INC |
| 02/05/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/17/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/11/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 12/11/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/11/2019 |
8-K
| Quarterly results |
| 11/15/2019 |
8-K
| Quarterly results |
| 11/14/2019 |
GN
| Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice |
| 11/12/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 10/17/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/04/2019 |
4
| Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 2,396 shares
@ $0.23, valued at
$551.1 |
|
| 09/23/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 09/17/2019 |
8-K
| Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation unde... |
| 08/08/2019 |
4
| Andrews Timothy K. (General Counsel & Secretary) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Disposed/sold 60,000 options to buy
@ $15.08, valued at
$904.8k
Disposed/sold 8,518 options to buy
@ $15, valued at
$127.8k
Disposed/sold 18,290 options to buy
@ $2.32, valued at
$42.4k
Disposed/sold 22,500 options to buy
@ $2.32, valued at
$52.2k
Granted 8,518 options to buy
@ $0.71, valued at
$6k
Granted 60,000 options to buy
@ $0.71, valued at
$42.6k
Granted 18,290 options to buy
@ $0.71, valued at
$13k
Granted 22,500 options to buy
@ $0.71, valued at
$16k
|
|
| 08/08/2019 |
4
| Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 70,000 shares
@ $0
Disposed/sold 25,000 options to buy
@ $20.19, valued at
$504.8k
Disposed/sold 5,600 options to buy
@ $15.08, valued at
$84.4k
Disposed/sold 20,000 options to buy
@ $2.37, valued at
$47.4k
Disposed/sold 8,750 options to buy
@ $2.32, valued at
$20.3k
Granted 25,000 options to buy
@ $0.71, valued at
$17.8k
Granted 5,600 options to buy
@ $0.71, valued at
$4k
Granted 8,750 options to buy
@ $0.71, valued at
$6.2k
Granted 20,000 options to buy
@ $0.71, valued at
$14.2k
|
|
| 08/08/2019 |
4
| Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 55,000 shares
@ $0
Disposed/sold 48,720 options to buy
@ $15.08, valued at
$734.7k
Disposed/sold 11,926 options to buy
@ $15, valued at
$178.9k
Disposed/sold 14,904 options to buy
@ $2.32, valued at
$34.6k
Disposed/sold 22,500 options to buy
@ $2.32, valued at
$52.2k
Granted 11,926 options to buy
@ $0.71, valued at
$8.5k
Granted 48,720 options to buy
@ $0.71, valued at
$34.6k
Granted 14,904 options to buy
@ $0.71, valued at
$10.6k
Granted 22,500 options to buy
@ $0.71, valued at
$16k
|
|
| 08/08/2019 |
4
| Beddingfield III Frederick (President & CEO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 150,000 shares
@ $0
Disposed/sold 190,910 options to buy
@ $15.08, valued at
$2.9M
Disposed/sold 42,590 options to buy
@ $15, valued at
$638.9k
Disposed/sold 40,968 options to buy
@ $2.32, valued at
$95k
Disposed/sold 93,750 options to buy
@ $2.32, valued at
$217.5k
Granted 42,590 options to buy
@ $0.71, valued at
$30.2k
Granted 190,910 options to buy
@ $0.71, valued at
$135.5k
Granted 40,968 options to buy
@ $0.71, valued at
$29.1k
Granted 93,750 options to buy
@ $0.71, valued at
$66.6k
|
|
| 08/08/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 07/03/2019 |
4
| Stroehmann Diane (See Remarks) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,095 shares
@ $0.76, valued at
$3.1k
|
|
| 07/03/2019 |
4
| Andrews Timothy K. (General Counsel & Secretary) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,095 shares
@ $0.76, valued at
$3.1k
|
|
| 07/03/2019 |
4
| Lizzul Paul F. (Chief Medical Officer) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,095 shares
@ $0.76, valued at
$3.1k
|
|
| 07/03/2019 |
4
| Azoy Alexander (CFO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,552 shares
@ $0.76, valued at
$1.2k
|
|
| 07/03/2019 |
4
| Beddingfield III Frederick (President & CEO) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 17,063 shares
@ $0.76, valued at
$13k
|
|
| 06/20/2019 |
GN
| Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference |
| 06/10/2019 |
GN
| Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology |
| 06/03/2019 |
4
| Burow Kristina (10% Owner) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.22, valued at
$30.5k
|
|
| 06/03/2019 |
4
| MORE ROBERT J (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.22, valued at
$30.5k
|
|
| 06/03/2019 |
4
| Leonard Keith R (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.22, valued at
$30.5k
|
|
| 06/03/2019 |
4
| Hindman James M. (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.22, valued at
$30.5k
|
|
| 06/03/2019 |
4
| Harris Todd (Director) has filed a Form 4 on Sienna Biopharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.22, valued at
$30.5k
|
|
|
|
|